Market revenue in 2023 | USD 159.6 million |
Market revenue in 2030 | USD 320.7 million |
Growth rate | 10.5% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 53.76% in 2023. Horizon Databook has segmented the Australia biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
Australia is a home to some of the world’s leading scientists, physicians and healthcare professionals. Every year, over 1,500 new clinical trials take place in Australia through pharmaceutical and biotechnology companies.
According to a report by the Australian government, early phase clinical trials are 28% cheaper than the U.S. before tax incentives and 60% cheaper after tax incentives. Between 2010 and 2015, Australia grew by more than 50 % in First in Human Trials (FIHT), representing the growing global recognition of the country.
Australian government spends around USD 3 billion each year to support medical research projects. The National Health and Medical Research Council (NHMRC) is the Australian Government’s main funding body.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into Australia biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account